Company Description
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs.
It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; and HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases.
The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus.
The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003.
Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 15, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Robb Knie |
Contact Details
Address: 590 Madison Avenue, 21st Floor New York, New York 10022 United States | |
| Phone | (646)756-2997 |
| Website | hoththerapeutics.com |
Stock Details
| Ticker Symbol | HOTH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.60 |
| CIK Code | 0001711786 |
| CUSIP Number | 44148G105 |
| ISIN Number | US44148G2049 |
| Employer ID | 82-1553794 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robb Knie | President, Chief Executive Officer and Chairman |
| David S. Briones | Chief Financial Officer |
| Hayley Springer | Executive Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2024 | ARS | Filing |
| Jun 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 18, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 17, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| Apr 22, 2024 | 424B3 | Prospectus |
| Apr 19, 2024 | EFFECT | Notice of Effectiveness |
| Apr 17, 2024 | UPLOAD | Filing |
| Apr 11, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 28, 2024 | 10-K | Annual Report |